Short answer
Definium Therapeutics, Inc. (DFTX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$67M
- −391.6% YoY · −57.4% QoQ
- EPS (diluted)
- −$0.75
- −581.8% YoY · −63.0% QoQ
Source: XBRL data from the Definium Therapeutics, Inc. (DFTX) Q3 2025 10-Q on SEC EDGAR. USD.
Definium Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Increased R&D expense due to accelerated Phase 3 trials for MM120 in GAD and MDD, driven by expanded participant enrollment and adaptive trial design
- Updated material risk: Volatility in fair value of 2022 USD Financing Warrants caused $22.5M loss in Q3 2025, reflecting increased share price since June 2025
- Regulatory risk: Ongoing FDA review with potential changes to Phase 3 trial designs for MM120 could delay approvals or increase costs
- Operational risk: Need to scale up personnel and commercial preparedness leading to 93% increase in G&A expenses to $14.7M in Q3 2025 impacting near-term cash burn
- Financial risk: Raised net proceeds of $242.8M in Oct 2025 equity offering, cash balance $209.1M as of Sept 30, 2025, expected to fund operations into 2028 under current plan
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Definium Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.